NCT03825289View on ClinicalTrials.gov

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 18, 2019

Primary Completion Date

January 15, 2025

Study Completion Date

March 31, 2029

Conditions
Metastatic Pancreatic CarcinomaStage II Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic CancerUnresectable Pancreatic Carcinoma
Interventions
DRUG

Hydroxychloroquine

Given PO

DRUG

Trametinib

Given PO

Trial Locations (2)

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

University of Utah

OTHER